InnoPharmax, Inc.(TW:4172)
NT$9.42+0.29 (+3.18%)
TW:4172
InnoPharmax, Inc. financials statements
NT$9.42
At close:+0.29 (+3.18%)
InnoPharmax, Inc. (4172) Ratios
InnoPharmax, Inc. Ratios
TW:4172's free cash flow for Q2 2026 was NT$-58.57M. For the 2026 fiscal year, TW:4172's free cash flow was decreased by NT$-370.00K and operating cash flow was NT$-58.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.52 | 10.90 | 5.57 | 3.49 | 14.72 |
| Quick Ratio | 3.20 | 10.27 | 4.91 | 2.73 | 13.63 |
| Cash Ratio | 1.95 | 5.67 | 1.16 | 1.04 | 6.37 |
| Solvency Ratio | -3.58 | -3.07 | -1.31 | -1.63 | -3.39 |
| Operating Cash Flow Ratio | -2.70 | -2.59 | -1.43 | -2.56 | -3.52 |
| Short-Term Operating Cash Flow Coverage | -13.11 | -7.62 | -4.17 | -4.30 | 1136.95 |
| Net Current Asset Value | NT$ 125.70M | NT$ 290.07M | NT$ 140.34M | NT$ 78.43M | NT$ 184.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.04 | 0.08 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | 0.05 | 0.09 | 0.01 |
| Debt-to-Capital Ratio | 0.03 | 0.02 | 0.04 | 0.08 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.05 | 1.10 | 1.14 | 1.05 |
| Debt Service Coverage Ratio | -15.88 | -8.96 | -4.49 | -3.77 | -197.09 |
| Interest Coverage Ratio | -448.46 | -312.64 | -176.19 | -363.14 | -186.87 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.02 | -0.00 |
| Interest Debt Per Share | 0.11 | 0.16 | 0.24 | 0.44 | 0.07 |
| Net Debt to EBITDA | 0.52 | 1.68 | 0.33 | 0.03 | 1.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 5.08% | 64.29% | 37.89% | -1.29% | 15.43% |
| EBIT Margin | -248.98% | -299.28% | -132.75% | -333.32% | -164.89% |
| EBITDA Margin | -239.81% | -278.82% | -117.03% | -304.59% | -145.17% |
| Operating Profit Margin | -248.98% | -297.18% | -140.73% | -320.35% | -154.76% |
| Pretax Profit Margin | -262.21% | -300.23% | -153.74% | -354.17% | -193.44% |
| Net Profit Margin | -267.29% | -307.43% | -153.74% | -354.17% | -193.44% |
| Continuous Operations Profit Margin | -267.29% | -307.43% | -153.74% | -354.17% | -193.44% |
| Net Income Per EBT | 101.94% | 102.40% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 105.32% | 101.03% | 109.24% | 110.56% | 125.00% |
| Return on Assets (ROA) | -39.32% | -15.68% | -13.51% | -21.09% | -16.72% |
| Return on Equity (ROE) | -43.99% | -16.47% | -14.89% | -23.94% | -17.49% |
| Return on Capital Employed (ROCE) | -40.98% | -15.90% | -13.23% | -20.73% | -13.72% |
| Return on Invested Capital (ROIC) | -39.92% | -15.52% | -12.80% | -19.53% | -13.61% |
| Return on Tangible Assets | -40.76% | -15.84% | -13.69% | -21.48% | -17.01% |
| Earnings Yield | -10.21% | -6.27% | -4.46% | -10.38% | -6.23% |
| Efficiency Ratios | |||||
| Receivables Turnover | 25.35 | 6.76 | 14.03 | 51.47 | 37.81 |
| Payables Turnover | 7.03 | 4.80 | 4.36 | 35.13 | 48.39 |
| Inventory Turnover | 4.02 | 0.63 | 1.29 | 0.98 | 2.61 |
| Fixed Asset Turnover | 20.16 | 3.76 | 3.35 | 1.49 | 3.49 |
| Asset Turnover | 0.15 | 0.05 | 0.09 | 0.06 | 0.09 |
| Working Capital Turnover Ratio | 0.33 | 0.14 | 0.36 | 0.20 | 0.32 |
| Cash Conversion Cycle | 53.24 | 558.39 | 226.05 | 368.07 | 142.03 |
| Days of Sales Outstanding | 14.40 | 53.99 | 26.01 | 7.09 | 9.65 |
| Days of Inventory Outstanding | 90.75 | 580.44 | 283.71 | 371.37 | 139.92 |
| Days of Payables Outstanding | 51.90 | 76.04 | 83.67 | 10.39 | 7.54 |
| Operating Cycle | 105.14 | 634.43 | 309.72 | 378.46 | 149.57 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.24 | -0.78 | -0.52 | -1.15 | -0.57 |
| Free Cash Flow Per Share | -1.24 | -0.79 | -0.53 | -1.16 | -0.59 |
| Dividend Paid and CapEx Coverage Ratio | -487.12 | -129.41 | -122.35 | -781.84 | -34.50 |
| Capital Expenditure Coverage Ratio | -487.12 | -129.41 | -122.35 | -781.84 | -34.50 |
| Operating Cash Flow Coverage Ratio | -12.14 | -4.95 | -2.26 | -2.66 | -8.97 |
| Operating Cash Flow to Sales Ratio | -1.95 | -2.36 | -1.05 | -3.44 | -1.04 |
| Free Cash Flow Yield | -7.46% | -4.85% | -3.08% | -10.08% | -3.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.82 | -15.93 | -22.54 | -9.63 | -16.08 |
| Price-to-Sales (P/S) Ratio | 26.19 | 49.03 | 34.47 | 34.11 | 31.07 |
| Price-to-Book (P/B) Ratio | 4.31 | 2.63 | 3.34 | 2.31 | 2.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.41 | -20.62 | -32.43 | -9.92 | -29.01 |
| Price-to-Operating Cash Flow Ratio | -13.44 | -20.77 | -32.70 | -9.93 | -29.85 |
| Price-to-Earnings Growth (PEG) Ratio | -0.15 | -0.47 | 0.62 | -0.79 | -0.18 |
| Enterprise Value Multiple | -10.40 | -15.90 | -29.12 | -11.16 | -20.19 |
| Enterprise Value | 1.72B | 1.43B | 1.57B | 990.66M | 1.41B |
| EV to EBITDA | -10.40 | -15.90 | -29.12 | -11.16 | -20.19 |
| EV to Sales | 24.94 | 44.34 | 34.08 | 34.00 | 29.31 |
| EV to Free Cash Flow | -12.77 | -18.65 | -32.07 | -9.89 | -27.36 |
| EV to Operating Cash Flow | -12.80 | -18.79 | -32.33 | -9.90 | -28.15 |
| Tangible Book Value Per Share | 3.72 | 6.12 | 5.06 | 4.87 | 5.95 |
| Shareholders’ Equity Per Share | 3.87 | 6.19 | 5.13 | 4.97 | 6.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | -0.02 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.64 | 0.33 | 0.50 | 0.34 | 0.55 |
| Net Income Per Share | -1.70 | -1.02 | -0.76 | -1.19 | -1.06 |
| Tax Burden | 1.02 | 1.02 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.00 | 1.16 | 1.06 | 1.17 |
| Research & Development to Revenue | 2.24 | 2.76 | 1.29 | 2.47 | 1.25 |
| SG&A to Revenue | 0.38 | 0.66 | 0.50 | 0.74 | 0.47 |
| Stock-Based Compensation to Revenue | 0.01 | 0.04 | 0.04 | 0.08 | 0.01 |
| Income Quality | 0.73 | 0.79 | 0.69 | 0.97 | 0.54 |
Currency in TWD
